Results 21 to 30 of about 3,657 (192)

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations

Drug Design, Development and Therapy, 2016
Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of ...
Hu MH, Zheng CL, Gao F
doaj   +1 more source

A novel antituberculosis agent exhibits potent clinical efficacy and good safety profile: an open-label, randomized-controlled, multicenter, phase 2a trial [PDF]

Signal Transduction and Targeted Therapy
Tuberculosis (TB) is a contagious disease that threatens human health worldwide. Combination chemotherapy is usually recommended for this disease. Recently, 2 nitroimidazole-based agents, namely, delamanid and pretomanid, have been approved by regulatory
Naihui Chu, Wenjuan Nie, Juan Du, Manni Wang, Liping Ma, Qingfeng Wang, Jun Wang, Xiaomeng Hu, Jin Wu, Yu Lu, Mailing Huang, Yuquan Wei, Zhenling Wang, Jian-Qing He, Zhenyu Ding, Xiawei Wei   +15 more
doaj   +2 more sources

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis [PDF]

New England Journal of Medicine, 2015
Treatment of multidrug-resistant Mycobacterium tuberculosis is a challenge. This letter describes the emergence of resistance to new therapies, bedaquiline and delamanid.
Bloemberg, Guido V., Keller, Peter M., Stucki, David, Stuckia, David, Trauner, Andrej, Borrell, Sonia, Latshang, Tsogyal, Coscolla, Mireia, Rothe, Thomas, Hömke, Rico, Ritter, Claudia, Feldmann, Julia, Schulthess, Bettina, Gagneux, Sebastien, Böttger, Erik C.   +14 more
openaire   +6 more sources

DprE2 is a molecular target of the anti-tubercular nitroimidazole compounds pretomanid and delamanid [PDF]

Nature Communications, 2023
Mycobacterium tuberculosis is one of the global leading causes of death due to a single infectious agent. Pretomanid and delamanid are new antitubercular agents that have progressed through the drug discovery pipeline.
Katherine A. Abrahams, Sarah M. Batt, Sudagar S. Gurcha, Natacha Veerapen, Ghader Bashiri, Gurdyal S. Besra   +5 more
doaj   +2 more sources

Delamanid in the Treatment of MDR/pre-XDR TB in Arkhangelsk Region in 2019–2021

Туберкулез и болезни лёгких, 2023
The objective: to evaluate the efficacy and safety of delamanid in a short-course treatment regimen for patients with MDR/pre-XDR pulmonary tuberculosis in Arkhangelsk Region from 2019 to 2021.Subjects and Methods.
E. S. Khimova, D. V. Perkhin, O. M. Sveshnikova, S. V. Makhmaeva, V. N. Verkhovaya, P. I. Eliseev, E. I. Nikishova, A. O. Maryandyshev   +7 more
doaj   +2 more sources

Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis

Perspectives in Clinical Research
Background: Bedaquiline and delamanid have been included in the individualized treatment regimen (ITR) to treat patients with drug-resistant tuberculosis (DR-TB).
Oki Nugraha Putra, Yulistiani Yulistiani, Soedarsono Soedarsono, Susi Subay   +3 more
doaj   +2 more sources

Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named “Regimen C” for pre-XDR tuberculosis in Niger [PDF]

Frontiers in Tuberculosis
BackgroundThe emergence of extensively drug-resistant tuberculosis (XDR-TB) poses a serious challenge to global tuberculosis control, particularly in high-burden countries like Niger. In 2021, a new fully oral, shorter treatment regimen, named regimen C,
Soumana Boubacar Soumana, Abdourahamane Yacouba, Abdourahamane Yacouba, Cheikh Aboubacar Abdoul Lawi, Ibrahim Oumar, Bassirou Souleymane, Alphazazi Soumana, Tapha Ounoussa, Mahamadou Doutchi, Mamane Daou, Souleymane Brah, Souleymane Brah, Eric Adehossi, Saidou Mamadou, Saidou Mamadou   +14 more
doaj   +2 more sources

Safety and outcome of bedaquiline and delamanid-based longer oral regimen in Indian children less than 5 years with drug-resistant tuberculosis [PDF]

Lung India
Background: Paediatric drug-resistant tuberculosis (DR-TB) remains a significant challenge, especially in high-burden countries like India. While bedaquiline (BDQ) and delamanid (DLM) are shown to be successful in treating multi-drug-resistant TB (MDR-TB)
Ira Shah, Ramsha Ansari, Dhruv N. Gandhi, Suhani Jain, Varsha Puri, Daksha Shah, Sanjay K. Mattoo, Minnie Bodhanwala   +7 more
doaj   +2 more sources

Natural polymorphisms in mycobacterium tuberculosis conferring resistance to delamanid in drug-naïve patients. [PDF]

, 2020
Mutations in the genes of the F420 signaling pathway, including dnn, fgd1, fbiA, fbiB, fbiC, and fbiD, of Mycobacterium tuberculosis (Mtb) complex can lead to delamanid resistance.
Wilkinson, R. J., Sander, P., Gagneux, S., Collantes, Jimena, Fenner, Lukas, Egger, Matthias, Reichmuth, Martina L, Avihingsanon, A., Borrell, Sonia, Keller, Peter Michael, International epidemiology Databases to Evaluate Aids,, Gagneux, Sebastien, Yotebieng, Marcel, Sander, Peter, Wilkinson, Robert J, Böttger, Erik C, Reichmuth, M. L., Zürcher, Kathrin, Fenner, L., Reinhard, Miriam, Avihingsanon, Anchalee, Loiseau, Chloé, Yotebieng, M., Zürcher, K., Reinhard, M., Egger, M., Keller, P. M., Keller, Peter M, Hömke, Rico, Collantes, J., Fenner, Lukas; https://orcid.org/, Reichmuth, Martina L., Homke, R., Borrell, S., International epidemiology Databases to Evaluate AIDS (IeDEA), Böttger, E. C., Loiseau, C.   +36 more
core   +3 more sources

Population Pharmacokinetics of Delamanid and its Main Metabolite DM-6705 in Drug-Resistant Tuberculosis Patients Receiving Delamanid Alone or Coadministered with Bedaquiline [PDF]

, 2022
BACKGROUND AND OBJECTIVE: Delamanid is a nitroimidazole, a novel class of drug for treating tuberculosis, and is primarily metabolized by albumin into the metabolite DM-6705.
Diacon, A.H., Svensson, E.M., Maartens, G., Dooley, Kelly E,, De Los Rios, Jorge, Diacon, Andreas H., Dooley, Kelly E., Dooley, Kelly E, Karlsson, Mats,, Diacon, Andreas H,, Upton, Caryn M, Shenje, J., Rios, J. De Los, Wiesner, Lubbe, Karlsson, M.O., Maartens, Gary, Upton, C.M., Tanneau, Lénaïg,, Svensson, Elin, Karlsson, Mats, Tanneau, L., Maartens, Gary,, Upton, Caryn M,, Upton, Caryn M., Shenje, Justin, Wiesner, L., De los rios, Jorge,, Wiesner, Lubbe,, Tanneau, Lénaïg, Diacon, Andreas H, Shenje, Justin,, Svensson, Elin,, Svensson, Elin M., Karlsson, Mats O.   +33 more
core   +1 more source